A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells
Shiyi Zhu, Lingli Shi, Linlin Huang, Ningxun Cui, Ruyue Chen, Lu Jiang, Annan Zhang, Yunyun Xu · 2026
Read A dual role of AcSDKP in chronic kidney disease: Targeting pericyte-driven fibrosis and vascular repair via VEGF/FGFR1 while eliciting a compensatory FGFR1 upregulation in apoptotic tubular cells by Shiyi Zhu, Lingli Shi, Linlin Huang, Ningxun Cui, Ruyue Chen, Lu Jiang, Annan Zhang, Yunyun Xu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0355409.txt.
Description
Shiyi Zhu and colleagues published a 2026 laboratory study in PLOS ONE on a small natural peptide called AcSDKP and its effects in chronic kidney disease. Using a mouse model of kidney injury plus cultured mouse and human cells, they asked how the peptide acts on the support cells that wrap tiny kidney blood vessels. They also asked how it acts on the tubule cells that filter waste.
The peptide protected blood vessels: it stopped support cells from turning into scar-forming cells and restored a growth signal that helps vessel linings regrow. Given early, it reduced scarring and improved kidney function in mice, while later treatment helped less. In badly damaged tubule cells, though, the same peptide sped up cell death by blocking a separate survival pathway. The work warns that any future therapy would need early use and careful targeting.
Catalog record
| CREATOR | Shiyi Zhu, Lingli Shi, Linlin Huang, Ningxun Cui, Ruyue Chen, Lu Jiang, Annan Zhang, Yunyun Xu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 54946 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |